Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

81. Screening for prostate cancer

Screening for prostate cancer Screening for prostate cancer Screening for prostate cancer Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J. Screening for prostate cancer. Rockville: Agency for Healthcare Research and Quality (...) (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 16. 2002 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing prostate cancer mortality and to assist the US Preventive Services Task Force in making recommendations on this topic. Authors' conclusions We are unable to determine the net benefit of screening because we cannot establish the presence and, if present, the magnitude of benefit from screening. We can

2002 Health Technology Assessment (HTA) Database.

82. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Ellison L, Cheli C D, Bright S, Veltri R W, Partin A W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prostate-specific antigen (PSA) for population-based prostate cancer screening. Five strategies were identified. These were total PSA (tPSA) 4.0 ng/mg, free PSA/tPSA (f/tPSA), and complexed PSA (cPSA) 3.8, 3.4, and 3.0 ng/mg. Type of intervention Screening. Economic study

2002 NHS Economic Evaluation Database.

83. A quantitative analysis of the costs and benefits of prostate cancer screening Full Text available with Trip Pro

, refer to the need for randomised controlled trials (including the analysis of serial screening over a longer term) to appropriately quantify the costs and benefits of prostate cancer screening. Source of funding None stated. Bibliographic details Benoit R M, Gronberg H, Naslund M J. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer and Prostatic Diseases 2001; 4(3): 138-145 PubMedID DOI Other publications of related interest Richie JP, Catalona WJ (...) A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening Benoit R M, Gronberg H, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed

2001 NHS Economic Evaluation Database.

84. Screening for prostate cancer, Norwegian review of international studies

the quality of life. Due to the insufficiencies in the current level of knowledge on prostate cancer, we lack the fundamental scientific knowledge on which to base decisions regarding those medical inventions best suited to prevent, diagnose or treat this disease. Efforts should be taken to increase our understanding of the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; Prostatic Neoplasms Language Published Norwegian Country of organisation Norway English (...) Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge

1999 Health Technology Assessment (HTA) Database.

85. Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)

Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives

To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostate cancer.

Authors' conclusions Mass screening for prostate cancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects

1999 Health Technology Assessment (HTA) Database.

86. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis

The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis Hoogendam A, Buntinx F, de Vet H C Authors' objectives To systematically review the literature in order to examine the diagnostic value of digital rectal (...) the studies, a narrative synthesis may have been more appropriate than statistical pooling. Nevertheless, the results appear to have been well pooled and the conclusions appear to be appropriate given the evidence. Implications of the review for practice and research Practice: The authors state that the DRE may have a place as an initial test when screening for prostate cancer. A negative result of DRE has a high predictive value. However, the moderate sensitivity should prevent the general practitioner

1999 DARE.

87. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

was used to describe the screening, diagnosis and therapy processes as costs for the screening examinations and costs for each newly diagnosed case of cancer in the form of type of cancer and therapy. Costs were calculated for the course of the disease, and all treatment measures were included. The cost for examination of suspected cases of cancer was calculated to be an average of two methods (fine-needle biopsy and transurethral resection) with microscopic examination of tissue from the prostate (...) , the natural history of the disease, and treatments, as well as on screening programmes. To this end, small-scale trials and modelling are recommended. Source of funding Financial support from the National Pharmacy Corporation's fund for research and studies in health economics and social pharmacy and the County Council of Ostergotland, Sweden. Bibliographic details Holmberg H, Carlsson P, Lofman O, Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme

1998 NHS Economic Evaluation Database.

88. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillat D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Selley S, Donovan J (...) , Faulkner A, Coast J, Gillat D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-96 Authors' objectives To summarise the available evidence on the diagnosis, management and screening of early localised prostate cancer. Authors' conclusions There is no justification for the introduction of population screening. PSA testing should be limited to men with clinical evidence of prostate cancer who have a life expectancy of more than 10 years

1997 Health Technology Assessment (HTA) Database.

89. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests')

. Unlike breast cancer screening, which has been shown to reduce mortality, prostate cancer screening has not yet been evaluated and there are several reasons why it may be less effective. Many men with prostate cancer never experience any ill effects because some tumours are slow growing and not aggressive. The most sensitive screening tests for prostate cancer are based on levels of prostate specific antigen (PSA). However, the PSA test and follow up biopsies cannot predict reliably whether a man has (...) for prostate cancer does more good than harm. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation England Address for correspondence University of York, York YO10 5DD, United Kingdom. Tel: +44 1904 321040; Fax: +44 1904 321041; Email: crd@york.ac.uk AccessionNumber 31999008344 Date bibliographic record published 21/01/1999 Date abstract record published 21/01/1999 Health

1997 Health Technology Assessment (HTA) Database.

90. Diagnosis, management and screening of early localised prostate cancer

in the follow-up of men with known prostate cancer, to monitor tumour progression. The 'gold' standard for staging localised disease is surgery, including lymphadenectomy. Clinical staging with DRE, PSA and TRUS is unreliable. There is only a 10% difference in survival rate between radical and conservative treatment. Conservative management is, therefore, a reasonable option for men with localised disease. In the absence of evidence from RCTs concerning the relative benefits of treatments, informed patient (...) Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillatt D Authors' objectives To assess the clinical and cost-effectiveness of methods for the diagnosis, treatment and screening of early localised prostate cancer. Searching EMBASE, Cancerlit, MEDLINE, the Social Sciences Citation Index

1997 DARE.

91. Future benefits and cost-effectiveness of prostate carcinoma screening

differentiated tumours. Cost results The cost per carcinoma detected for men aged 55-70 years was $2,905. The cost per person screened for prostate specific antigen and digital rectal examination for African-American men was $849. Improving the specificity of screening tests has great cost reduction potential. Synthesis of costs and benefits Costs and benefits were not combined into cost-utility ratios. Authors' conclusions Current diagnostic trends toward the persistent increased detection of localised (...) prostate carcinoma in younger men, combined with a marked reduction in distant stage disease, suggest significant potential mortality reductions. These trends may have greater implications for African-American men. Potential economic savings might be made by only screening high-risk men. CRD COMMENTARY - Selection of comparators The reason for the choice of the comparator is clear. Validity of estimate of measure of benefit The benefit measure should have included patient-derived utility assessment

1997 NHS Economic Evaluation Database.

92. Cost-effectiveness analysis of prostatic cancer screening

. Bibliographic details Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H. Cost-effectiveness analysis of prostatic cancer screening. Nippon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 1997; 88(10): 892-899 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Humans; Japan; Male; Mass Screening /economics; Middle Aged; National Health Programs; Prostatic Neoplasms /economics /prevention & control AccessionNumber 21998006202 Date (...) Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

1997 NHS Economic Evaluation Database.

93. [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis]

that EDR and the serum dosage of PSA are necessary and adequate methods in the programme of early diagnosis and screening of prostate neoplasms. Prostate echography should be reserved for cases of doubt and for the exclusion of needle biopsy. These measures also result in an optimisation of health expenditure. CRD COMMENTARY - Selection of comparators The reason for the choice of comparator is clear. The programme of early diagnosis of prostate cancer is based on a combination of different methods:EDR (...) [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis] Screening del carcinoma prostatico in pazienti disurici: protocolli diagnostici e rapporto costi/benefici [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis] Screening del carcinoma prostatico in pazienti disurici: protocolli diagnostici e rapporto costi/benefici [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols

1997 NHS Economic Evaluation Database.

94. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

1995 Health Technology Assessment (HTA) Database.

95. Costs and effectiveness of prostate cancer screening in elderly men

knowledge about prostate cancer, it may be reasonable for Medicare to consider reimbursement of the screening test. Reimbursement could be seen as ensuring that out-of-pocket screening expenses (however small) not impede well-informed discussion and decision-making between physician and patient. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Aged; Mass Screening; Medicare; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Radiation /therapy Language Published English (...) Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made

1995 Health Technology Assessment (HTA) Database.

96. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men

Gustafsson O, Carlsson P, Norming U, Nyman C R, Svensson H. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men. Prostate 1995; 26(6): 299-309 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Humans; Male; Mass Screening /economics /methods; Middle Aged; Physical Examination; Predictive Value of Tests; Prostate-Specific Antigen /blood; Prostatic Neoplasms (...) Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Gustafsson O, Carlsson P

1995 NHS Economic Evaluation Database.

97. Prostate cancer screening in a large corporation population

Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Kantrowitz W, Doyle J, Semeraro J, Krane R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Prostate cancer screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Male employees of the Polaroid Corporation aged between 50 and 65 years. Setting Occupational. A large public corporation medical department in the United States. Dates to which data relate The start date of the screening programme was unclear. Resources used and costs were presented for the actual programme. The price year

1995 NHS Economic Evaluation Database.

98. An economic rationale for prostate cancer screening

of the effectiveness data, where possible, could be useful. Implications of the study More research is necessary for the assessment of the mortality rates. Bibliographic details Benoit R M, Naslund M J. An economic rationale for prostate cancer screening. Urology 1994; 44(6): 795-803 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Breast Neoplasms /prevention & Cost-Benefit Analysis; Costs and Cost Analysis; Fee Schedules; Female; Humans; Male; Mass Screening /economics; Middle Aged; Prostatic (...) An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening Benoit R M, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

1994 NHS Economic Evaluation Database.

99. Screening for prostate cancer: a decision analytic view

Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Krahn M D, Mahoney J E, Eckman M H, Trachtenberg J, Pauker S G, Detsky A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS) and digital rectal examination (DRE). Type of intervention Screening/secondary prevention. Economic study type Cost-utility analysis. Study population Cohorts of men between the ages of 50 and 70. Setting Medical centre. The economic study was carried out in Ontario (Canada). Dates to which data relate Dates for effectiveness and resource

1994 NHS Economic Evaluation Database.

100. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination

A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination Love R R, Fryback D G, Kimbrough S R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for stage-B prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Men, aged 60 years and over. Setting The study was carried out in the USA. Dates to which data relate Price related to 1984. Source of effectiveness data Review of studies. Modelling Epidemiological cohort model (model

1985 NHS Economic Evaluation Database.